A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

This study has been completed.

Sponsor:

Collaborator:

University of California, Los Angeles

Information provided by:

National Institute on Drug Abuse (NIDA)

ClinicalTrials.gov Identifier:

NCT00033111

First received: April 5, 2002

Last updated: July 21, 2008

Last verified: July 2008

History of Changes

Purpose

The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Cabergoline	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cabergoline Cabergoline diphosphate

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

New Use
reduction of severity of cocaine dependence


Estimated Enrollment:	140
Study Start Date:	June 2001
Study Completion Date:	April 2004

Detailed Description:

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of child-bearing potential using proper method of birth control.

Exclusion Criteria:

Additional criteria available during screening at the site.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033111

Locations


United States, California
Torrance Clinic
Torrance, California, United States, 90502
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of California, Los Angeles

Investigators


Principal Investigator:	Steve Shoptaw, Ph.D.	Friends Research Institute, Inc.

More Information

No publications provided


ClinicalTrials.gov Identifier:	NCT00033111 History of Changes
Obsolete Identifiers:	NCT00024895
Other Study ID Numbers:	NIDA-CTO-0007-1
Study First Received:	April 5, 2002
Last Updated:	July 21, 2008
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:


Cocaine-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Cabergoline Anti-Dyskinesia Agents Antineoplastic Agents Antiparkinson Agents	Central Nervous System Agents Dopamine Agents Dopamine Agonists Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses

ClinicalTrials.gov processed this record on March 03, 2015

To Top